Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine S Grasso

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Virchows Archiv : an International Journal of Pathology|December 16, 2014
Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinomaJoshua I Warrick, Daniel H Hovelson, Anmol Amin, et al.
BMC Cancer|May 9, 2020
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potentialEric T Miller, Sungyong You, Radu M Cadaneanu, et al.
Human Pathology|August 7, 2014
HRAS mutations are frequent in inverted urothelial neoplasmsAndrew S McDaniel, Yali Zhai, Kathleen R Cho, et al.
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Nature Medicine|July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Molecular Cancer Research : MCR|January 17, 2015
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes TumorsAndi K Cani, Daniel H Hovelson, Andrew S McDaniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without IpilimumabTheodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, et al.
Nature Communications|February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonistGiulia Parisi, Justin D Saco, Felix B Salazar, et al.
Nature Genetics|April 8, 2014
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine gliomaKathryn R Taylor, Alan Mackay, Nathalène Truffaux, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Virchows Archiv : an International Journal of Pathology|December 16, 2014
Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinomaJoshua I Warrick, Daniel H Hovelson, Anmol Amin, et al.
BMC Cancer|May 9, 2020
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potentialEric T Miller, Sungyong You, Radu M Cadaneanu, et al.
Human Pathology|August 7, 2014
HRAS mutations are frequent in inverted urothelial neoplasmsAndrew S McDaniel, Yali Zhai, Kathleen R Cho, et al.
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Nature Medicine|July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Molecular Cancer Research : MCR|January 17, 2015
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes TumorsAndi K Cani, Daniel H Hovelson, Andrew S McDaniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without IpilimumabTheodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, et al.
Nature Communications|February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonistGiulia Parisi, Justin D Saco, Felix B Salazar, et al.
Nature Genetics|April 8, 2014
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine gliomaKathryn R Taylor, Alan Mackay, Nathalène Truffaux, et al.
Pageof 4